LZZ-02
LZZ-02 is an orally active Tankyrase 1/2 inhibitor. LZZ-02 reduces c-Myc levels and inhibits the transcriptional activity of the WNT/β-catenin pathway. LZZ-02 exhibits anticancer activity against colon cancer. LZZ-02 can be used in studies related to colorectal cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 37418-69-2
- 分子式: C15H12N2O3
- 分子量:268.27
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
LZZ-02 (0.1-100 μM; 24 h) potently inhibits LiCl (HY-Y0649)-induced β-catenin transcriptional activity in HEK293 cells, with an IC50 of 10 μM[2].
LZZ-02 (100 μM; 24 h) potently inhibits Wnt3a-induced β-catenin transcriptional activity in HEK293 cells[2].
LZZ-02 inhibits β-catenin transcriptional activity induced by β-catenin overexpression in HEK293 cells[2].
LZZ-02 (1-100 μM; 24 h) dose-dependently decreases the protein levels of β-catenin, c-Myc and Cyclin D1, while upregulates the protein level of Axin2, in DLD1 colorectal cancer cells[2].
LZZ-02 (30 μM) upregulates the protein level of Axin2 and reduces the protein level of β-catenin in SW480 colorectal cancer cells[2].
LZZ-02 (30 μM; days 1-9) inhibits the proliferation of DLD1 and SW480 colorectal cancer cells, with an effect comparable to that of XAV939[2].
LZZ-02 (30 μM; 2 weeks) inhibits colony formation of DLD1 and SW480 colorectal cancer cells[2].
LZZ-02 inhibits the proliferation of colorectal cancer cell line DLD-1 in vitro[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DLD1 colorectal cancer cells
-
Concentration:1-100 μM (β-catenin, c-Myc, Cyclin D1 analysis); 30 μM (Axin2 analysis)
-
Incubation Time:24 h
-
Result:Reduced the protein levels of β-catenin, c-Myc, and Cyclin D1 in a dose-dependent manner, with noticeable decreases starting at 25 μM.
Significantly increased Axin2 protein levels while strongly decreasing β-catenin levels at 30 μM.
-
Cell Line:DLD1 and SW480 colorectal cancer cells
-
Concentration:30 μM
-
Incubation Time:1-9 days
-
Result:Significantly reduced cell viability in both DLD1 and SW480 cells over the 9-day period, with viability reduced by approximately 20% compared to untreated controls by day 9.
Showed inhibition efficiency comparable to the reference compound XAV939.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (6-week-old female; subcutaneous xenograft model induced by implantation of 2.5 × 106 DLD1 cells)[2]
-
Dosage:30 mg/kg
-
Administration:p.o.; daily; 18 days
-
Result:Reduced average tumor weight to 0.26 g at day 18 post-treatment, compared to 1 g in the control group.
Caused no significant change in mouse body weight during the treatment period.
化学情報
-
CAS 番号 37418-69-2
-
分子量 268.27
-
分子式 C15H12N2O3
-
SMILES
O=C(C1=CC=CC=C1)/C=C/NC2=CC=C(C=C2)[N+]([O-])=O
-
別名
ZINC13406363
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Pećina-Šlaus N, et al. Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. International journal of molecular sciences. 2023 Apr 04;24(7):6733. [Content Brief]
[2]. Li B, et al. Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening. Molecules (Basel, Switzerland). 2020 Apr 06;25(7):1680. [Content Brief]
[3]. Yu M, et al. Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer. Journal of medicinal chemistry. 2022 Apr 14;65(7):5244-5273. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
LZZ-02 関連分類
HY-183474 関連分類
Powered by Bioz